nonalcoholic fatty liver disease 非酒精性脂肪肝

nonalcoholic fatty liver disease
繁: 非酒精性脂肪肝
簡: 非酒精性脂肪肝

團隊指出，由於現時沒有治療非酒精性脂肪肝的藥物已取得美國食物及藥物管理局（FDA）認可，今次研發對於治療這方面的疾病尤其重要；他們已於十多個管轄區為新藥申請專利，包括美國、歐洲等。 

理大中大研發治療肥胖相關藥物　最快一兩年後臨床測試 (2023年5月22日)。香港電台，取自https://news.rthk.hk/rthk/ch/component/k2/1701578-20230522.htm

The new drug, ABarginase, which can treat prediabetes, type 2 diabetes and nonalcoholic fatty liver disease, recently won the grand prize at the Geneva International Exhibition of Inventions.

Breakthrough in treating diseases linked to obesity (2023, May 23). The Standard. Retrieved from https://www.thestandard.com.hk/section-news/section/4/252684/Breakthrough-in-treating-diseases-linked-to-obesity